Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Azacitidine + CAG in R/R AML
NCT05807347Phase 2Recruiting
- Sponsor
- Hematology Department, 920th Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in acute myeloid leukemia (AML), sponsored by Hematology Department, 920th Hospital. Started Feb 2023; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05807347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05807347.